Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector

Almeida, Juliana Franco; Breyner, Natália Martins; Mahi, M.; Ahmed, Bakr; Benbouziane, Bouasria; Boas, Priscilla C. B. Vilas; Miyoshi, Anderson; Azevedo, Vasco; Langella, Philippe; Bermúdez‐Humarán, Luis G.; Châtel, Jean-Marc

doi:10.1016/j.vaccine.2016.01.022

Cited by 16 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, enhancements to the lactococcal vaccine delivery system are continuously being carried out, amongst which, includes the recent incorporation of the cell-surface anchored fibronectin binding protein A (FnBPA) from Staphylococcus aureus which functions to increase immunomodulatory properties of L. lactis strains during mucosal delivery as a live DNA vaccine vector [119, 120]. L. lactis shuttle vectors such as the pNZ:vig [121] and pPERDBY reporter plasmid [122] for the delivery of DNA vaccines to mammalian cells have also been developed and in the latter shown to perform efficiently in the absence of invasive proteins or relevant chemical treatments.…”

Section: Lactococcus Lactis As a Cell Factorymentioning

confidence: 99%

A review on Lactococcus lactis: from food to factory

et al. 2017

View full text Add to dashboard Cite

Lactococcus lactis has progressed a long way since its discovery and initial use in dairy product fermentation, to its present biotechnological applications in genetic engineering for the production of various recombinant proteins and metabolites that transcends the heterologous species barrier. Key desirable features of this gram-positive lactic acid non-colonizing gut bacteria include its generally recognized as safe (GRAS) status, probiotic properties, the absence of inclusion bodies and endotoxins, surface display and extracellular secretion technology, and a diverse selection of cloning and inducible expression vectors. This have made L. lactis a desirable and promising host on par with other well established model bacterial or yeast systems such as Escherichia coli, Salmonella cerevisiae and Bacillus subtilis. In this article, we review recent technological advancements, challenges, future prospects and current diversified examples on the use of L. lactis as a microbial cell factory. Additionally, we will also highlight latest medical-based applications involving whole-cell L. lactis as a live delivery vector for the administration of therapeutics against both communicable and non-communicable diseases.

show abstract

Section: Lactococcus Lactis As a Cell Factorymentioning

confidence: 99%

A review on Lactococcus lactis: from food to factory

et al. 2017

View full text Add to dashboard Cite

show abstract

“…53 Positive results have been obtained in animal models and human clinical trials using probiotics, especially using recombinant lactic acid bacteria expressing beneficial molecules as a live system delivered to inflammatory sites. [54][55][56][57] The anti-inflammatory effects of the Lactococcus lactis strain, which produces 15-lipoxygenase-1, were shown to be effective in preventing intestinal damage and in alleviating trinitrobenzenesulfonic acid-induced colitis in an experimental murine model. 57 In addition, genetically modified L. lactis expressing cytokines, such as human interleukin-10 (IL-10), has been shown to prevent intestinal damage in experimental colitis.…”

Section: Next-generation Probioticsmentioning

confidence: 99%

New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases

2016

View full text Add to dashboard Cite

The interaction between the gut microbiota and the host immune system is very important for balancing and resolving inflammation. The human microbiota begins to form during childbirth; the complex interaction between bacteria and host cells becomes critical for the formation of a healthy or a disease-promoting microbiota. C-section delivery, formula feeding, a high-sugar diet, a high-fat diet and excess hygiene negatively affect the health of the microbiota. Considering that the majority of the global population has experienced at least one of these factors that can lead to inflammatory disease, it is important to understand strategies to modulate the gut microbiota. In this review, we will discuss new insights into gut microbiota modulation as potential strategies to prevent and treat inflammatory diseases. Owing to the great advances in tools for microbial analysis, therapeutic strategies such as prebiotic, probiotic and postbiotic treatment and fecal microbiota transplantation have gained popularity.

show abstract

“…Among these vectors, one of the probiotic strains, lactic acid bacteria (LAB), has raised a lot of interest due to its beneficial properties for human health [2]. To date, a large number of protective antigens have been previously delivered by LAB strains, mainly including Lactococcus lactic (L. lactic) [3][4][5] and Lactobacillus plantarum (L. plantarum) strains [6,7]. Compared with L. lactic strains, the L. plantarum strains are able to colonize more efficiently in the intestinal tract, which is the first step for efficient antigen production and necessary for subsequent antigen processing in host cells.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory Properties of Lactobacillus plantarum NC8 Expressing an Anti-CD11c Single-Chain Fv Fragment

Liu¹,

Yang²,

Gao³

et al. 2019

Journal of Microbiology and Biotechnology

View full text Add to dashboard Cite

The lactic acid bacteria species Lactobacillus plantarum (L. plantarum) has been used extensively for vaccine delivery. Considering to the critical role of dendritic cells in stimulating host immune response, in this study, we constructed a novel CD11c-targeting L. plantarum strain with surface-displayed variable fragments of anti-CD11c, single-chain antibody (scFv-CD11c). The newly designed L. plantarum strain, named 409-aCD11c, could adhere and invade more efficiently to bone marrow-derived DCs (BMDCs) in vitro due to the specific interaction between scFv-CD11c and CD11c located on the surface of BMDCs. After incubation with BMDCs, the 409-aCD11c strain harboring a eukaryotic vector pValac-GFP could lead to more efficient expression of GFP compared with wild-type strains shown by flow cytometry analysis, indicating the enhanced translocation of pValac-GFP from L. plantarum to BMDCs. Similar results were also observed in an in vivo study, which showed that oral administration resulted in efficient expression of GFP in both Peyer's patches (PP) and mesenteric lymph nodes (MLNs) within 7 days after the last administration. In addition, the CD11c-targeting strain significantly promoted the differentiation and maturation of DCs, the differentiation of IL-4 + and IL-17A + T helper (Th) cells in MLNs, as well as production of B220 + IgA + B cells in the PP. In conclusion, this study developed a novel DC-targeting L. plantarum strain which could increase the ability to deliver eukaryotic expression plasmid to host cells, indicating a promising approach for vaccine study.

show abstract

Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector

Cited by 16 publications

References 31 publications

A review on Lactococcus lactis: from food to factory

A review on Lactococcus lactis: from food to factory

New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases

Immunomodulatory Properties of Lactobacillus plantarum NC8 Expressing an Anti-CD11c Single-Chain Fv Fragment

Contact Info

Product

Resources

About